# Acumen Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/acumen-pharmaceuticals

- Industry: Biotechnology
- Headquarters: Charlottesville, US
- Website: www.acumenpharm.com
- Total disclosed funding: $21M
- Latest round: Series A (Apr 25, 2013)
- Investors on record: 4

## About

Based in Virginia, US, and founded in 1996 by Grant A. Krafft, Acumen Pharmaceuticals, Inc. aka Acumen, operates as a research and drug development company providing treatment solutions for Alzheimer’s disease by helping in reducing soluble oligomers of the amyloid-beta peptide in Alzheimer's disease. The company is a publicly-traded company on NASDAQ by the ticker name of ABOS. As of March 2022, the employee count was 17 and As of Dec 2020, the revenue was 10.4 Million. In April 2013, Acumen Pharmaceuticals, Inc. raised USD 20 million in series A funding led by BFV Partners, with participation from Glynn Capital and Praxis Technologies, NeuroVentures also participated in the round. 

The company offers ACU193 as an anti-amyloid-beta oligomer (AßO) monoclonal antibody (mAb) and prevents toxic ABOs from binding to dendritic spines thereby perving neural function. ACU193 was a research development between Acumen and Merck.

## Funding rounds

- Series A, Apr 25, 2013, $20M — Glynn Capital, NeuroVentures, BVF Partners, Praxis Technologies
- Series A, Apr 18, 2013, $0.7M — NeuroVentures

## Investors

- NeuroVentures (https://capitalatlas.ai/funds/neuroventures) — Series A
- Glynn Capital (https://capitalatlas.ai/funds/glynn-capital) — Series A
- BVF Partners (https://capitalatlas.ai/funds/bvf-partners) — Series A
- Praxis Technologies — Series A